BLRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioLine RX Ltd (BLRX) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available. The technical indicators are neutral to bearish, options data shows no significant sentiment, and the company's financial performance has deteriorated significantly in the latest quarter. There are no positive catalysts or recent news to support a buy decision.
The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 52.144, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 2.729, and resistance is at 3.079. Overall, the technical outlook is neutral to bearish.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The company's financials for Q3 2025 show a significant decline in revenue (-91.36% YoY) and net income (-83.22% YoY). Gross margin also dropped by 3.65%. No recent congress trading data or influential figure activity was reported.
In Q3 2025, revenue dropped to $427,000 (-91.36% YoY), net income fell to -$977,000 (-83.22% YoY), and gross margin declined to 80.33 (-3.65% YoY). EPS remained flat at 0. The financial performance is weak, with no signs of growth.
No data available for analyst ratings or price target changes.
